3,5-二氯联苯-3-羧酸 | 380228-57-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二氯联苯-3-羧酸
• 英文名称: 3',5'‐dichloro‐(1,1'‐biphenyl)‐3‐carboxylic acid
• 英文别名: 3',5'-dichloro[1,1'-biphenyl]-3-carboxylic acid；3-(3,5-dichlorophenyl)benzoic Acid
• CAS: 380228-57-9
• 化学式: C₁₃H₈Cl₂O₂
• 分子量: 267.111
• InChiKey: DJCRAGQDESWSPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-苯氧基苯磺酰胺 、 3,5-二氯联苯-3-羧酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 3',5'-dichloro-N-((4-phenoxyphenyl)sulfonyl)[1,1'-biphenyl]-3-carboxamide
  参考文献：
  名称：

  SAR by Interligand Nuclear Overhauser Effects (ILOEs) Based Discovery of Acylsulfonamide Compounds Active against Bcl-x_Land Mcl-1

  摘要：

  Overexpression of antiapoptotic members of the Bcl-2 family proteins, such as Bcl-x(L), and Mfl-1, has been shown to be involved in resistance to chemotherapeutic drugs in many forms of cancers. Recent efforts from the Abbott Laboratories resulted in the development of the acylsulfonamide compound and clinical candidate that targets selectively Bcl-2, Bcl-x(L), and Bcl-w while it is not active against Mcl-1 and Bfl-1. However, early clinical and preclinical studies suggest that pan-Bcl-2 antagonists, targeting simultaneously Mcl-1, Bcl-x(L), and possibly all other four antiapoptotic Bcl-2 proteins, may result in more efficacious drugs. Here, following an NMR fragment-based approach, SAR by ILOEs, we report on compounds that exhibit nanomolar affinities for both Bcl-x(L) and Mcl-1 in vitro. We believe that these molecules can be used as useful starting point for the development of novel Bcl-2 antagonists, in particular targeting Mcl-1.

  DOI：

  10.1021/jm200826s
• 作为产物：
  描述：

  3,5-二氯碘苯 在 potassium permanganate 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙醇 、 丙酮 、 甲苯 为溶剂， 反应 34.0h， 生成 3,5-二氯联苯-3-羧酸
  参考文献：
  名称：

  Diflunisal类似物稳定运甲状腺素蛋白的天然状态。有效抑制淀粉样蛋白生成。

  摘要：

  合成了FDA批准的非甾体抗炎药diflunisal的类似物，并将其评估为转甲状腺素蛋白（TTR）聚集（包括淀粉样蛋白原纤维形成）的抑制剂。对于26种化合物观察到高抑制活性。其中，八种在人血浆中对TTR表现出优异的结合选择性（结合化学计量比> 0.50，每个TTR四聚体理论上最多结合有2.0种抑制剂）。生物物理研究表明，这八种抑制剂可在168小时的时间内显着减慢四聚体的解离（淀粉样蛋白生成的速率决定步骤）。这似乎是通过基态稳定化来实现的，这提高了四聚体解离的动力学势垒。这八种抑制剂对WT TTR的动力学稳定作用进一步得到证实，淀粉样蛋白原纤维形成的速率随抑制剂浓度（pH 4.4）的增加而降低。TTR.18（2）和TTR.20（2）配合物的X射线共晶体结构揭示了18和20在TTR结合位点以相反的方向结合。将氟从18的间位移至20的邻位可逆转结合方向，使20的亲水性芳环在外部结合袋中取向，其中羧

  DOI：

  10.1021/jm030347n

文献信息

• METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES
  申请人：KELLY Jeffery W.

  公开号：US20120065237A1

  公开（公告）日：2012-03-15

  Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.

  动力学稳定化甲状腺素转运蛋白的天然状态是防止蛋白质错误折叠的有效机制。因为甲状腺素转运蛋白的错误折叠在甲状腺素转运蛋白淀粉样疾病中扮演重要角色，抑制这种错误折叠可以用作有效的治疗或预防这种疾病的方法。本文公开了治疗方法。
• Methods for treating transthyretin amyloid diseases
  申请人：Kelly W. Jeffery

  公开号：US20070078186A1

  公开（公告）日：2007-04-05

  Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.

  转甲状腺素原生态稳定化是预防蛋白质错构的有效机制，因为转甲状腺素的错构在转甲状腺素淀粉样病中扮演着重要角色，抑制此类错构可用作该类疾病的有效治疗或预防。披露了治疗方法。
• A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences
  作者：Julius Pollinger、Simone Schierle、Leonie Gellrich、Julia Ohrndorf、Astrid Kaiser、Pascal Heitel、Apirat Chaikuad、Stefan Knapp、Daniel Merk

  DOI：10.1021/acsmedchemlett.9b00306

  日期：2019.9.12

  The nuclear retinoid X receptors (RXRs) are key ligand sensing transcription factors that serve as universal nuclear receptor heterodimer partners and are thus involved in numerous physiological processes. Therapeutic targeting of RXRs holds high potential but available RXR activators suffer from limited safety. Selectivity for RXR subtypes or for certain RXR heterodimers are promising strategies for safer RXR modulation. Here, we report systematic structure activity relationship studies on biphenyl carboxylates as new RXR ligand chemotype. We discovered specific structural modifications that enhance potency on RXRs, govern subtype preference, and vary modulation of different RXR heterodimers. Fusion of these structural motifs enabled specific tuning of subtype preferential profiles with markedly improved potency. Our results provide further evidence that RXR subtype selective ligands can be designed and present a novel chemotype of RXR modulators that can be tuned for subtype and heterodimer preferences.
• MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE AND KETO-PIPERAZINE COMPOUNDS
  申请人：Palatin Technologies, Inc.

  公开号：EP1919479A2

  公开（公告）日：2008-05-14
• Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds
  申请人：SHARMA D. Shubh

  公开号：US20060287332A1

  公开（公告）日：2006-12-21

  Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where X, W, J, Q, L 1 , L 2 , L 3 , R 1a , R 1b , R 2a , and R 2b are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.